Skip to main
  1. Stocks
  2. Coya Therapeutics Inc
  3. Forecast
COYA

COYA Stock Forecast & Price Target

COYA Analyst Ratings

Based on 5 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Coya Therapeutics is viewed favorably because its lead asset, COYA 302, is advancing in a high-unmet-need ALS program with full enrollment of 120 participants in the ALSTARS Phase 2/3 trial, FDA Fast Track designation, and top-line data expected in early 2Q27. The investment case is strengthened by the company’s Treg-modulation thesis, supported by prior preclinical and clinical signals of improved Treg health, reduced systemic inflammation, and positive early ALS and FTD biomarker and function data, including a Phase 2 ALS study and an FTD IND accepted for Phase 2a initiation in 2H26. Financially, Coya reported a net loss of $6.6M in 2Q26 and held $43.2M in cash and cash equivalents, with management guiding runway into 2H27, giving it time to reach key catalysts before needing additional capital.

Bears say

Coya Therapeutics is a clinical-stage biotechnology company whose valuation depends heavily on unproven programs, so any clinical or regulatory setback could sharply reduce the prospects for its Treg-based therapies. The company faces multiple fundamental risks, including failure to demonstrate clinically meaningful efficacy, delays or refusal of approval in the U.S. and/or EU, and slower-than-anticipated market penetration of COYA 302 in ALS, all of which could impair future commercialization. It also may require additional capital to fund operations, and such financing could be unavailable or substantially dilutive, while competitive, reimbursement, and partnership risks further weaken the investment case.

COYA has been analyzed by 5 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Coya Therapeutics Inc and is not a guaranteed prediction by Public.com or investment advice.

COYA Analyst Forecast & Price Prediction

Get the latest COYA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in COYA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Coya Therapeutics Inc (COYA) Forecast

Analysts have given COYA a Strong Buy based on their latest research and market trends.

According to 5 analysts, COYA has a Strong Buy consensus rating as of Nov 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $15, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $15, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Coya Therapeutics Inc (COYA)


COYA Analyst Forecast & Price Prediction

Get the latest COYA stock forecast, including analyst ratings and price predictions, with real-time AI-powered fundamental data and custom analysis

Start investing in COYA

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.
Uncover COYA stock data and trends